Serious side effects sideline small Roche study of an experimental Huntington’s drug from Ionis
Two years after in-licensing an experimental antisense drug for Huntington’s disease from Ionis, Roche investigators have been forced to halt a small early-stage study in the wake of a pair of serious side effects.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 158,600+ biopharma pros reading Endpoints daily — and it's free.